Sign Out
Renal cell carcinoma (RCC): CABOMETYX is indicated as monotherapy for advanced renal cell carcinoma: as first-line treatment of adult patients with intermediate or poor risk (see Pharmacology: Pharmacodynamics under Actions); in adults following prior vascular endothelial growth factor (VEGF)-targeted therapy (see Pharmacology: Pharmacodynamics under Actions).
CABOMETYX, in combination with nivolumab, is indicated for the first-line treatment of advanced renal cell carcinoma in adults (see Pharmacology: Pharmacodynamics under Actions).
Hepatocellular carcinoma (HCC): CABOMETYX is indicated as monotherapy for the treatment of hepatocellular carcinoma (HCC) in adults who have previously been treated with sorafenib.
Differentiated thyroid carcinoma (DTC): CABOMETYX is indicated as monotherapy for the treatment of adult patients with locally advanced or metastatic differentiated thyroid carcinoma (DTC), refractory or not eligible to radioactive iodine (RAI) who have progressed during or after prior systemic therapy.
